- Companies
- Orasis Pharmaceuticals
Orasis Pharmaceuticals Funding, Investors & Competitors
Orasis Pharmaceuticals has raised $126M across 4 funding rounds, most recently a $15M Series A in October 2024.
Last Orasis Pharmaceuticals funding round
$15M
Series A · Oct 2024
Cumulative funding Orasis Pharmaceuticals raised
$126M
across 4 funding rounds
Key investors in Orasis Pharmaceuticals
Sequoia Capital
Visionary Venture Fund
SBI Japan-Israel Innovation Fund
Catalio Capital Management
LifeSci Venture Partners
Bluestem Capital
Johnson & Johnson Innovation
Maverick Ventures
About Orasis Pharmaceuticals
Orasis Pharmaceuticals is a clinical-stage biopharma company based in Givatayim, Israel, advancing presbyopia treatments through topical eye drops. Its lead candidate, CSF-1, combines carbachol and pilocarpine to dynamically adjust pupil size for near vision correction, demonstrating efficacy in Phase 3 trials with over 80% of participants achieving three-line visual acuity improvements. The drop targets the 1.8 billion global presbyopia population, offering a non-invasive alternative to reading glasses. Orasis partners with Santen Pharmaceutical for commercialization in Asia and advances regulatory submissions in the U.S. and Europe.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
Orasis Pharmaceuticals Funding History
Orasis Pharmaceuticals has raised a total of $126M across 4 funding rounds.
Orasis Pharmaceuticals' first fundraising round was a $13M Series B in June 2018. The most recent completed round was a $15M Series A in October 2024.
Orasis Pharmaceuticals funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Oct 2024 | Series A | Catalio Capital Management (lead) | $15M | Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company, completed a $78 million financing on October 8, 2024, to support the commercial launch of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel corrective eye drop for presbyopia in adults. The financing included a $68 million Series D equity component co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc., with participation from Catalio Capital Management, Freepoint Capital Group, and returning investors such as Visionary Ventures, Bluestem Capital, SBI (Japan) Innovation Fund, Sequoia Capital, and Maverick Ventures. Concurrent with the equity raise, Orasis secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing. Qlosi received FDA approval in October 2023 and targets early-stage presbyopia patients with a low-concentration, preservative-free formulation offering improved efficacy, comfort, and fewer side effects compared to competitors. Catalio lists Orasis in its portfolio under structured opportunities. |
| Oct 2024 | Series D | Arboretum Ventures (lead); Johnson & Johnson Innovation (lead); Alderline Group; Bluestem Capital; SBI Japan-Israel Innovation Fund; Catalio Capital Management; Sequoia Capital; Visionary Venture Fund | $68M | Orasis Pharmaceuticals, an ophthalmic pharmaceutical company based in Ponte Vedra, Florida, completed a $78 million financing on October 8, 2024, to support the commercial launch of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel corrective eye drop for presbyopia in adults. The financing included a $68 million Series D equity component co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc., with participation from Catalio Capital Management, Freepoint Capital Group, returning investors Visionary Ventures, Bluestem Capital, SBI (Japan) Innovation Fund, Sequoia Capital, Maverick Ventures, and others. Concurrently, Orasis secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing. Qlosi received FDA approval in October 2023 and represents a low-dose pilocarpine solution aimed at improving near vision while balancing efficacy and tolerability. The funding will enable the U.S. commercial launch, targeting presbyopes seeking alternatives to reading glasses. Investors highlighted the market potential and confidence in the Orasis team's execution, as noted by Arboretum Ventures' Managing Partner Paul McCreadie. Founded in 2015, Orasis focuses on reshaping vision possibilities through innovative ophthalmic solutions, backed by life science and healthcare investors. The company is led by industry executives and eyecare specialists. |
| Sep 2020 | Series C | Bluestem Capital (lead); Visionary Venture Fund (lead); SBI Japan-Israel Innovation Fund; LifeSci Venture Partners; Maverick Ventures; Sequoia Capital | $30M | Orasis Pharmaceuticals, an Israeli ophthalmic pharmaceutical company, develops an innovative eye drop candidate, CSF-1, to treat presbyopia symptoms as a non-invasive alternative to reading glasses. Presbyopia affects nearly 2 billion people worldwide, causing long-sightedness due to lens elasticity loss, typically in middle and old age. The CSF-1 drop demonstrated statistically significant improvements in distance-corrected near visual acuity in a phase 2b trial completed in October 2019. On September 10, 2020, Orasis closed a $30 million Series C financing round, co-led by new investor Bluestem Capital and returning investor Visionary Venture Fund, with participation from Sequoia Capital, SBI Japan-Israel Innovation Fund, Maverick Ventures Israel, LifeSci Venture Partners, and others. The funds are designated to advance CSF-1 through phase 3 clinical trials (NEAR-1 and NEAR-2 initiated shortly after) and support pre-commercialization activities ahead of potential product launch. Bluestem's Tyler J. Stowater joined the board. CEO Elad Kedar highlighted the round as completing capitalization for phase 3 trials and fueling initial commercialization strategy, noting strong investor confidence from both new and returning backers. Investors expressed optimism about Orasis leading in presbyopia treatment, citing the team's clinical and commercial approach and the molecule's established safety profile. This followed a prior Series B round two years earlier, with total funding reaching approximately $81 million across three rounds by that point. |
| Jun 2018 | Series B | Visionary Venture Fund (lead); SBI Japan-Israel Innovation Fund; LifeSci Venture Partners; Sequoia Capital | $13M | Orasis Pharmaceuticals, a clinical-stage pharmaceutical company based in Herzliya, Israel, develops innovative eye drops for treating presbyopia symptoms. Its lead product candidate, CSF-1, targets presbyopia, a condition affecting nearly two billion people worldwide, offering a noninvasive alternative to reading glasses. On June 5, 2018, Orasis closed a $13 million Series B financing round led by Visionary Venture Fund, with participation from Sequoia Capital, SBI Japan-Israel Innovation Fund, LifeSci Venture Partners, and other private investors. Jeffry Weinhuff of Visionary Venture Fund and Masafuyu Tanaka of SBI joined the board. The funds supported advancement of CSF-1 through Phase 2b clinical trials, preparation for Phase 3, and pre-commercial activities. |
Who has invested in Orasis Pharmaceuticals?
10 investors have backed Orasis Pharmaceuticals across its funding rounds, including Sequoia Capital, Visionary Venture Fund, SBI Japan-Israel Innovation Fund, Catalio Capital Management, LifeSci Venture Partners and Bluestem Capital.
Lead investors include Catalio Capital Management, Arboretum Ventures, Johnson & Johnson Innovation, Bluestem Capital and Visionary Venture Fund.
Orasis Pharmaceuticals Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Jun 2018 | ||
| 3 | Participant | Jun 2018 | ||
| 3 | Lead | Jun 2018 | ||
| 2 | Lead | Sep 2020 | ||
| 2 | Participant | Jun 2018 | ||
| 2 | Lead | Oct 2024 | ||
| 1 | Participant | Oct 2024 | ||
| 1 | Lead | Oct 2024 | ||
This data is available for Pro users. Sign up to see all 10 Orasis Pharmaceuticals investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialOrasis Pharmaceuticals Competitors
Orasis Pharmaceuticals competitors include listed companies like IDEXX Laboratories, GE HealthCare, United Imaging and Glaukos, and private ones like Dental Monitoring and AcuityMD.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x | ||
| Private | $91M | - | $1B | - | ||
| Private | - | - | $955M | - |
Orasis Pharmaceuticals Public Comps
Orasis Pharmaceuticals is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Orasis Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Orasis Pharmaceuticals
| When was Orasis Pharmaceuticals founded? | Orasis Pharmaceuticals was founded in 2015. |
| Where is Orasis Pharmaceuticals headquartered? | Orasis Pharmaceuticals is headquartered in Jacksonville, FL, United States. |
| Is Orasis Pharmaceuticals publicly listed? | No, Orasis Pharmaceuticals is a private, VC-backed company. |
| How much funding has Orasis Pharmaceuticals raised? | Orasis Pharmaceuticals has raised $126M across 4 funding rounds. |
| What was Orasis Pharmaceuticals' last funding round? | Orasis Pharmaceuticals' last funding round was a $15M Series A in October 2024, led by Catalio Capital Management. |
| Who are Orasis Pharmaceuticals' investors? | Orasis Pharmaceuticals' investors include SBI Japan-Israel Innovation Fund, Sequoia Capital, Visionary Venture Fund, Bluestem Capital, LifeSci Venture Partners, Catalio Capital Management, Alderline Group, Arboretum Ventures, Maverick Ventures and Johnson & Johnson Innovation. |
| Which companies are comparable to Orasis Pharmaceuticals? | Companies comparable to Orasis Pharmaceuticals include IDEXX Laboratories, GE HealthCare, United Imaging, Glaukos, Dental Monitoring and AcuityMD. |
See companies similar to Orasis Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




